Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Current ratio
Novo Nordisk A/S's current ratio at the end of the quarter to 30 June 2026 was 0.9×, up 0.1× from fiscal 2025 (0.8×). Over the past ten years it has ranged from 0.7× (fiscal 2024) to 1.3× (fiscal 2015); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 0.8× | 8.10% |
| FY2024 | 0.7× | (10.13%) |
| FY2023 | 0.8× | (7.99%) |
| FY2022 | 0.9× | 4.01% |
| FY2021 | 0.9× | (8.16%) |
| FY2020 | 0.9× | (11.56%) |
| FY2019 | 1.1× | (2.90%) |
| FY2018 | 1.1× | (14.59%) |
| FY2017 | 1.3× | 1.34% |
| FY2016 | 1.3× | (6.61%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 0.9× | 10.84% |
| Mar 2026 | 0.8× | (1.51%) |
| Dec 2025 | 0.8× | 3.03% |
| Sep 2025 | 0.8× | (1.01%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 1.6× |
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| SNY Sanofi compare | 1.1× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVS Novartis AG compare | 0.9× |
| NVO Novo Nordisk A/S | 0.9× |
| GSK GSK PLC Sponsored ADR compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement